查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2015179

非血管支架市場：依產品類型、材質、應用和最終用戶分類－2026-2032年全球市場預測

Non-vascular Stents Market by Product Type, Material Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025 年非血管支架市場價值為 15.3 億美元，預計到 2026 年將成長至 15.9 億美元，複合年成長率為 5.18%，到 2032 年將達到 21.8 億美元。

主要市場統計數據
基準年 2025 15.3億美元
預計年份：2026年 15.9億美元
預測年份 2032 21.8億美元
複合年成長率 (%) 5.18%

對非血管支架進行全面概述，重點介紹其廣泛的臨床應用、技術進步以及影響其在各個專科領域應用的策略因素。

隨著臨床醫生和醫療設備製造商積極應對不斷擴大的適應症和不斷發展的手術標準，非血管支架在介入醫學中發揮著至關重要的作用。這些器械可用於治療多種非血管腔內病變，提供機械支撐，維持通暢性，並支持在氣道、膽道、胃腸道和泌尿系統道等部位進行微創手術。其廣泛應用得益於先進的手術技術、跨學科協作以及門診和以患者為中心的治療模式的轉變。在這種環境下，器械的性能和易用性對臨床工作流程和病患管理能力有顯著的影響。

在引入非血管支架的過程中，關鍵的技術、程序和循證變革正在重新定義器械設計、臨床路徑和採購重點。

近年來，非血管支架在醫療保健系統中的設計、評估和應用發生了變革性的變化。首先，材料創新已超越了漸進式改進，實現了針對特定解剖和病理情況的客製化解決方案。合金工程和鎳鈦諾加工技術提高了支架的徑向強度和適應性，而聚合物材料則為生物相容性和藥物傳遞提供了新的策略，為輔助性治療開闢了新的可能性。

2025 年的關稅措施將如何重塑供應鏈、製造地和採購方式？這些措施將對醫療設備的經濟性和取得產生哪些長期影響？

美國對非血管支架產品徵收關稅並於2025年逐步提高關稅，對相關製造商、經銷商和臨床服務提供者產生了一系列複雜的下游影響。關稅政策增加了進口原料和成品的成本壓力，進而波及供應鏈談判、庫存策略以及與醫療系統的價格談判。更重要的是，關稅也促使許多機構重新評估供應商多元化和近岸外包策略，以此作為穩定投入成本和前置作業時間的手段。

將臨床應用、產品類型、材料和最終用戶趨勢與可行的商業化優先事項聯繫起來的策略性細分洞察。

對於希望將產品開發和商業策略與臨床實際情況相契合的相關人員而言，精準理解市場區隔至關重要。按應用領域分析，該市場涵蓋呼吸系統、膽道系統、消化系統和泌尿器官系統適應症。呼吸系統領域進一步細分為支氣管和氣管亞領域，而消化系統領域則進一步細分為結直腸、十二指腸和食道應用。泌尿系統領域也類似地分為前列腺、輸尿管和尿道應用，每種應用都有其獨特的解剖結構挑戰、臨床終點和治療流程，這些因素都會影響器械的形狀、徑向強度和傳輸機制。

制定區域策略，協調全球主要市場中非血管支架部署的監管複雜性、採購行為和臨床多樣性。

區域趨勢對監管路徑、採購行為和臨床導入模式有顯著影響，因此需要針對每個全球市場制定差異化的策略。美洲地區呈現異質性環境，先進的臨床能力和多樣化的支付模式並存。監管機構強調支持上市後監測和報銷談判的臨床證據，而採購決策往往受到醫療機構層級委員會和基於價值的合約的影響。

競爭格局分析揭示了成熟公司、專業創新者和本地參與企業如何在臨床證據、物流和商業模式方面競爭。

非血管支架領域的競爭動態由成熟的醫療設備製造商、專業創新企業和新興區域性企業組成，它們各自採取不同的臨床應用和市場滲透路徑。成熟企業專注於整合產品系列、建立強大的分銷網路，並致力於將器械與服務和培訓項目相結合，以減少操作差異，加速臨床醫生對產品的接受度。這些成熟企業通常會投資於長期實證醫學研究，並參與指南制定，以鞏固其臨床應用偏好。

製造商應採取切實可行的優先事項，以確保臨床可靠性、加強供應鏈，並調整其商業策略以適應不斷變化的醫療保健服務模式。

產業領導企業需要採取果斷行動，將技術潛力轉化為穩固的市場地位，同時降低營運和監管風險。首先，製造商應優先考慮符合支付方和監管機構期望的臨床證據策略，並投資於可操作的註冊研究和真實世界研究，以證明能夠顯著降低再次手術率、縮短住院時間和降低手術總成本。這些證據將有助於產品被納入醫院處方清單，並支持基於價值的合約談判。

我們嚴謹的混合方法研究途徑，結合對臨床醫生的訪談、監管和臨床證據的整合以及供應鏈分析，確保了可操作和檢驗的見解。

本研究整合了從臨床文獻、監管申報文件、醫療設備註冊信息和相關人員訪談中獲得的一手和二手信息，構建了非血管支架市場趨勢的全面圖景。一手研究包括對介入醫師、採購經理和監管專家進行結構化訪談，以了解手術趨勢、證據預期和購買行為。這些定性研究結果與臨床試驗數據、同行評審文章和公開的監管文件進行了交叉比對，以確保技術準確性和臨床相關性。

綜合分析最後強調了創新、證據產生和運作韌性的整合，這決定了非血管支架對相關人員的長期成功。

非血管支架正從一系列獨立的器械類別轉變為一個相互關聯的領域，材料科學、輸送技術和醫療保健系統優先事項在此交匯融合，共同決定著臨床和商業性的成功。該市場的特點是越來越重視可驗證的患者療效、門診和住院環境中的營運效率，以及能夠抵禦地緣政治和關稅相關壓力的、高度靈活的供應鏈。這些因素將使那些能夠將可靠的臨床證據與切實可行的生產和分銷策略相結合的企業獲得回報。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 非血管支架市場：依產品類型分類

  • 球囊擴張型
  • 自膨脹

第9章 非血管支架市場：依材料類型分類

  • 鎳鈦諾
  • 聚合物
  • 不銹鋼

第10章 非血管支架市場：依應用領域分類

  • 呼吸道
    • 支氣管
    • 氣管
  • 膽道
  • 消化器官系統
    • 冒號
    • 十二指腸
    • 食道
  • 泌尿器官系統
    • 攝護腺
    • 輸尿管
    • 尿道

第11章 非血管支架市場：依最終用戶分類

  • 門診手術中心
  • 醫院

第12章 非血管支架市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 非血管支架市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 非血管支架市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國非血管支架市場

第16章：中國非血管支架市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • B. Braun Melsungen AG
  • Becton, Dickinson and Company
  • Boston Scientific Corporation
  • Cook Medical LLC
  • Endo International plc
  • Hobbs Medical, Inc.
  • Medtronic plc
  • Merit Medical Systems, Inc.
  • Taewoong Medical Co., Ltd.
  • Teleflex Incorporated
Product Code: MRR-036C5CF3B534

The Non-vascular Stents Market was valued at USD 1.53 billion in 2025 and is projected to grow to USD 1.59 billion in 2026, with a CAGR of 5.18%, reaching USD 2.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 1.53 billion
Estimated Year [2026] USD 1.59 billion
Forecast Year [2032] USD 2.18 billion
CAGR (%) 5.18%

A comprehensive orientation to non-vascular stents highlighting clinical breadth, technological evolution, and the strategic drivers shaping adoption across specialties

Non-vascular stents now occupy a pivotal role in interventional medicine as clinicians and device manufacturers respond to expanding clinical indications and evolving procedural standards. These devices address an array of luminal pathologies beyond the vascular system, providing mechanical support, maintaining patency, and enabling minimally invasive approaches across airway, biliary, gastrointestinal, and urological domains. Adoption is driven by increasing procedural sophistication, cross-specialty collaboration, and a shift toward outpatient and ambulatory care settings where device performance and ease of deployment materially affect clinical workflow and patient throughput.

Recent technological refinements, such as improvements in alloy metallurgy, polymer coatings, and delivery systems, have reduced complication rates and improved device longevity. As a result, clinicians are more willing to select stents for complex anatomies and repeatable interventions. Concurrently, health systems are prioritizing tools that reduce length of stay and rehospitalization, so product value is judged not only by immediate clinical efficacy but also by impact on downstream resource utilization. Regulatory pathways have matured in several jurisdictions, clarifying evidence thresholds for market access and post-market surveillance, which in turn shapes manufacturer investment strategies.

Transitioning care models and intensifying scrutiny from payers mean that companies must align device performance with clear health economic narratives. Manufacturers who combine robust clinical data with streamlined logistics and tactical engagement with procurement stakeholders will be best positioned to influence formularies and procedural guidelines. In sum, the non-vascular stents landscape is defined by technical progress, procedural diffusion across specialties, and the increasing necessity of aligning clinical value with system-level outcomes.

Major technological, procedural, and evidence-based shifts that are redefining device design, clinical pathways, and procurement priorities in non-vascular stent adoption

The recent period has witnessed transformative shifts reshaping how non-vascular stents are designed, evaluated, and deployed within health systems. First, material innovation has progressed beyond incremental changes to enable purpose-built solutions for specific anatomical and pathological contexts. Alloy engineering and nitinol processing now support enhanced radial force and conformability while polymeric materials offer alternative strategies for biointegration and drug delivery, opening new opportunities for adjunctive therapies.

Second, procedural pathways have realigned as minimally invasive techniques proliferate across specialties. Interventional pulmonology, gastroenterology, and urology increasingly adopt image-guided, endoscopic, and combined hybrid approaches, which in turn demand delivery systems optimized for precision and reduced trauma. Consequently, device design has become more user-centric, focusing on ease of deployment, reduced procedure time, and compatibility with existing procedural suites.

Third, healthcare delivery models are shifting care toward ambulatory and outpatient settings where throughput and predictable outcomes drive purchasing decisions. This shift compels manufacturers to refine sterilization, packaging, and logistics to meet ambulatory surgical center requirements. Lastly, the integration of real-world evidence into regulatory and payer conversations has accelerated. Real-world registries and pragmatic studies now supplement controlled trials to demonstrate comparative performance and economic impact, informing clinician preference and reimbursement discussions. Collectively, these shifts emphasize that future competitiveness will depend on integrated solutions that combine clinical efficacy, operational efficiency, and demonstrable economic value.

How 2025 tariff measures are reshaping supply chains, manufacturing footprints, and procurement behaviors with long-term implications for device economics and access

The imposition and escalation of tariffs by the United States in 2025 have created a complex set of downstream effects for manufacturers, distributors, and clinical providers engaged with non-vascular stents. Tariff policy has introduced incremental cost pressures on imported raw materials and finished devices, which in turn reverberate through supply chain negotiations, inventory strategies, and pricing conversations with health systems. Importantly, tariffs have also prompted many organizations to re-evaluate supplier diversity and nearshoring as mechanisms to stabilize input costs and lead times.

In response to tariff-driven cost volatility, manufacturers have pursued several tactical responses. Some have accelerated localization of manufacturing and assembly operations to mitigate exposure to import duties, while others have sought tariff classifications and compliance strategies to limit duty burdens. These choices affect capital allocation and site selection, with implications for regulatory filings and quality system harmonization. Distributors and hospitals have adjusted procurement cadence, increasing safety stock and extending contract negotiations to incorporate tariff contingency clauses that protect margins and operational continuity.

Beyond direct financial effects, tariffs have shifted competitive dynamics. Domestic producers with integrated local supply chains have gained relative pricing advantage in certain product categories, enabling more aggressive contracting with large health systems. Conversely, smaller suppliers reliant on global sourcing have faced compressed margins and have prioritized higher-value SKUs or strategic partnerships. On the clinical side, purchasing stakeholders have heightened scrutiny of total cost of care rather than unit price alone, seeking transparency on lifecycle costs, reintervention rates, and service agreements. Overall, the tariff environment in 2025 has catalyzed supply chain reconfiguration, influenced strategic investment decisions, and increased the importance of resilient sourcing and differentiated value propositions.

Strategic segmentation insights that map clinical applications, product types, materials, and end-user dynamics to actionable commercialization priorities

A nuanced understanding of segmentation is essential for stakeholders seeking to align product development and commercial strategies with clinical realities. When analyzed by application, the market spans airway, biliary, gastrointestinal, and urological indications, with the airway category further disaggregated into bronchial and tracheal subsegments and the gastrointestinal category further parsed into colorectal, duodenal, and esophageal uses. The urological domain likewise differentiates into prostatic, ureteral, and urethral applications, each presenting distinct anatomical challenges, clinical endpoints, and procedural workflows that influence device geometry, radial strength, and delivery mechanisms.

Product type delineation separates balloon-expandable devices from self-expanding constructs, a distinction that informs deployment technique, requirement for adjunctive imaging, and suitability for tortuous or dynamic lumens. Material type remains a foundational axis of differentiation, as nitinol imparts superelasticity and conformability, polymeric solutions offer alternative biodegradation profiles and drug elution opportunities, and stainless steel provides legacy performance characteristics and cost considerations. End-user segmentation distinguishes ambulatory surgical centers from hospitals, and this distinction carries strategic implications for packaging, sterilization standards, inventory turnover, and sales channel engagement.

Taken together, these segmentation lenses produce a matrix of clinical, operational, and commercial variables that companies must navigate. Product teams should map device specifications to specific anatomical and procedural needs, while commercial leaders must tailor messaging and pricing to the procurement realities of ambulatory versus inpatient settings. In addition, R&D prioritization should balance material innovations with regulatory tractability and manufacturing scalability to ensure that new offerings address discrete clinical gaps and system-level requirements.

Regional strategies that reconcile regulatory complexity, procurement behaviors, and clinical diversity across major global markets for non-vascular stent deployment

Regional dynamics exert a profound influence on regulatory pathways, procurement behavior, and clinical adoption patterns, requiring differentiated strategies across global markets. The Americas region presents a heterogeneous environment where advanced clinical capabilities coexist with diverse payer models; regulatory expectations emphasize post-market surveillance and clinical evidence that supports reimbursement negotiations, while procurement decisions often hinge on institution-level committees and value-based contracting arrangements.

In Europe, Middle East & Africa, stakeholders encounter a mosaic of national regulatory frameworks and budgetary pressures that elevate the importance of cost-effectiveness and outcomes data; localized clinical practice variations and national procurement policies necessitate tailored market access approaches and country-level evidence generation. Asia-Pacific encompasses both advanced healthcare systems and rapidly developing markets, yielding a spectrum of needs from high-complexity device demand to cost-sensitive solutions, with manufacturing ecosystems and supply chain nodes that can support regional production and distribution strategies.

Collectively, these regions demand that manufacturers balance global lifecycle management with localized intelligence. Market entry plans should incorporate regulatory timing, reimbursement pathways, and strategic partnerships that reflect regional clinical practice and procurement culture. Moreover, supply chain design and commercial models must adapt to regional logistics, manufacturing capabilities, and health system priorities to ensure sustainable adoption and scalable growth across distinct geographic contexts.

Competitive landscape analysis revealing how incumbents, specialized innovators, and regional entrants compete on clinical evidence, logistics, and commercial models

Competitive dynamics in the non-vascular stents space reflect a mix of established medical device firms, specialized innovators, and emerging regional players, each pursuing different pathways to clinical adoption and market penetration. Established firms emphasize integrated portfolios, robust distribution networks, and the ability to bundle devices with service offerings and training programs that reduce procedural variability and accelerate clinician uptake. These incumbents often invest in long-term evidence generation and guideline engagement to solidify clinical preference.

Specialized innovators, by contrast, target niche anatomical or procedural challenges with focused technological differentiation-such as novel material science, hybrid drug-device combinations, or delivery systems optimized for complex geometries. These firms frequently leverage early clinical partnerships and investigator-initiated studies to validate performance and to build key opinion leader support. Regional manufacturers and new entrants compete on cost and local regulatory agility, offering pragmatic alternatives in cost-sensitive markets and exploiting proximity to regional supply chains to shorten lead times.

Across competitor types, successful companies align clinical development with clear economic narratives that speak to hospital administrators and ambulatory surgical centers alike. Additionally, channel strategy matters: direct sales models can foster closer clinician engagement and post-market support, while distributor partnerships can accelerate reach in fragmented markets. Ultimately, competitive advantage will accrue to organizations that combine clinical credibility, supply chain resilience, and commercial models tailored to the procedural and procurement realities of their target segments.

Actionable priorities for manufacturers to secure clinical credibility, strengthen supply chains, and align commercial strategies with evolving care delivery models

Industry leaders must act decisively to convert technological promise into durable market positions while mitigating operational and regulatory risks. First, manufacturers should prioritize clinical evidence strategies that align with payer and regulatory expectations, investing in pragmatic registries and real-world studies that demonstrate meaningful reductions in reintervention, length of stay, and overall procedural cost. This evidence will support both hospital formulary inclusion and value-based contracting conversations.

Second, supply chain resilience should be elevated to a strategic priority. Companies ought to diversify sourcing, consider nearshoring for critical components, and build inventory strategies that account for tariff volatility and logistics disruptions. Concurrently, commercial teams must tailor go-to-market approaches for ambulatory surgical centers and hospitals, customizing service offerings, training programs, and packaging to meet differing operational constraints. Investing in clinician education and procedural standardization will reduce variability and accelerate adoption.

Third, product roadmaps should balance material innovation with manufacturability and regulatory tractability, favoring incremental clinical gains that address well-defined procedural gaps. Cross-functional alignment among R&D, regulatory, and commercial teams will accelerate time-to-market and ensure market-fit. Finally, leaders should explore strategic partnerships and selective M&A to expand capabilities in drug-eluting technologies, polymer science, or regional manufacturing capacity. By executing on these priorities, companies can create defensible differentiation and sustain growth in an increasingly competitive landscape.

Rigorous mixed-method research approach combining clinician interviews, regulatory and clinical evidence synthesis, and supply chain analysis to ensure actionable and validated insights

This research synthesizes primary and secondary inputs across clinical literature, regulatory filings, device registries, and stakeholder interviews to construct a comprehensive view of the non-vascular stents landscape. Primary research included structured interviews with interventional clinicians, procurement leaders, and regulatory experts to capture procedural trends, evidence expectations, and purchasing behaviors. These qualitative insights were triangulated with analyses of clinical trial data, peer-reviewed publications, and publicly available regulatory documents to ensure technical accuracy and clinical relevance.

Secondary sources encompassed manufacturer product information, device labeling, and professional society guidelines to contextualize device features and recommended usage. Supply chain and manufacturing considerations were analyzed through import/export data, materials sourcing reports, and interviews with logistics providers to assess vulnerabilities and operational strategies. Analytical methods included thematic coding of qualitative data, cross-validation of clinical outcomes from multiple studies, and scenario analysis to evaluate tariff and supply chain contingencies. Throughout, an iterative review process ensured alignment between clinical realities and commercial implications, and subject-matter experts validated key findings to maintain methodological rigor and relevance for decision-makers.

Concluding synthesis highlighting the convergence of innovation, evidence generation, and operational resilience that will determine long-term success for non-vascular stent stakeholders

Non-vascular stents are transitioning from a set of discrete device categories into an interconnected domain where material science, delivery technology, and health system priorities intersect to determine clinical and commercial success. The market is characterized by heightened emphasis on demonstrable patient outcomes, operational efficiency in ambulatory and hospital settings, and adaptive supply chains that can withstand geopolitical and tariff-related pressures. These forces will reward organizations that integrate robust clinical evidence with pragmatic manufacturing and distribution strategies.

Looking forward, competition will intensify around differentiated materials and user-centric delivery systems that address specific anatomical challenges, while regulatory and payer landscapes will prioritize real-world performance and cost-effectiveness. Organizations that proactively align R&D investment with reimbursement imperatives and that cultivate partnerships to extend clinical validation will shape practice patterns and procurement choices. In conclusion, success in the non-vascular stents domain will hinge on the ability to translate technical innovation into measurable system-level value and to execute resilient commercialization strategies that meet the needs of clinicians, patients, and health system buyers.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Non-vascular Stents Market, by Product Type

  • 8.1. Balloon-Expandable
  • 8.2. Self-Expanding

9. Non-vascular Stents Market, by Material Type

  • 9.1. Nitinol
  • 9.2. Polymeric
  • 9.3. Stainless Steel

10. Non-vascular Stents Market, by Application

  • 10.1. Airway
    • 10.1.1. Bronchial
    • 10.1.2. Tracheal
  • 10.2. Biliary
  • 10.3. Gastrointestinal
    • 10.3.1. Colorectal
    • 10.3.2. Duodenal
    • 10.3.3. Esophageal
  • 10.4. Urological
    • 10.4.1. Prostatic
    • 10.4.2. Ureteral
    • 10.4.3. Urethral

11. Non-vascular Stents Market, by End User

  • 11.1. Ambulatory Surgical Center
  • 11.2. Hospitals

12. Non-vascular Stents Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Non-vascular Stents Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Non-vascular Stents Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Non-vascular Stents Market

16. China Non-vascular Stents Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Abbott Laboratories
  • 17.6. B. Braun Melsungen AG
  • 17.7. Becton, Dickinson and Company
  • 17.8. Boston Scientific Corporation
  • 17.9. Cook Medical LLC
  • 17.10. Endo International plc
  • 17.11. Hobbs Medical, Inc.
  • 17.12. Medtronic plc
  • 17.13. Merit Medical Systems, Inc.
  • 17.14. Taewoong Medical Co., Ltd.
  • 17.15. Teleflex Incorporated

LIST OF FIGURES

  • FIGURE 1. GLOBAL NON-VASCULAR STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL NON-VASCULAR STENTS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL NON-VASCULAR STENTS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA NON-VASCULAR STENTS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL NON-VASCULAR STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BALLOON-EXPANDABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BALLOON-EXPANDABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BALLOON-EXPANDABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY SELF-EXPANDING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY SELF-EXPANDING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY SELF-EXPANDING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY NITINOL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY NITINOL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY NITINOL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY POLYMERIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY POLYMERIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY POLYMERIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BRONCHIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BRONCHIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BRONCHIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY TRACHEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY TRACHEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY TRACHEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BILIARY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BILIARY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY BILIARY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY COLORECTAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY COLORECTAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY COLORECTAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY DUODENAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY DUODENAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY DUODENAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY ESOPHAGEAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY ESOPHAGEAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY ESOPHAGEAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY PROSTATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY PROSTATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY PROSTATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY URETERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY URETERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY URETERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY URETHRAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY URETHRAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY URETHRAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY AMBULATORY SURGICAL CENTER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. GCC NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GCC NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 145. GCC NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 146. GCC NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 147. GCC NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. G7 NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 168. G7 NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 169. G7 NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 170. G7 NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 171. G7 NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. NATO NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 176. NATO NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 177. NATO NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 178. NATO NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 179. NATO NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL NON-VASCULAR STENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA NON-VASCULAR STENTS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA NON-VASCULAR STENTS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA NON-VASCULAR STENTS MARKET SIZE, BY MATERIAL TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA NON-VASCULAR STENTS MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA NON-VASCULAR STENTS MARKET SIZE, BY AIRWAY, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA NON-VASCULAR STENTS MARKET SIZE, BY GASTROINTESTINAL, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA NON-VASCULAR STENTS MARKET SIZE, BY UROLOGICAL, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA NON-VASCULAR STENTS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)